Niraparib Maintenance Improves PFS in Frontline Ovarian Cancer

January 20, 2020
Antonio Gonzalez Mart

Antonio Gonzalez Martín, MD, discusses the results from the phase III PRIMA study, which evaluated the PARP inhibitor niraparib versus placebo as a frontline treatment of patients with newly diagnosed ovarian cancer who responded to platinum-based chemotherapy.

AntonioGonzález Martín, MD, co-director, Department of Medical Oncology,ClínicaUniversidad de Navarra, discusses the results from the phase III PRIMA study, which evaluated the PARP inhibitor niraparib (Zejula) versus placebo as a frontline treatment of patients with newly diagnosed ovarian cancer who responded to platinum-based chemotherapy.

Two analyses were performed on these patients in the PRIMA trial, and the primary end point of this study was progression-free survival (PFS), Gonzalez-Martin says. First, patients that tested positive for homologous recombination deficiency (HRD) were analyzed.

Patients who tested positive for HRD demonstrated a median PFS of 21.9 months with niraparib versus 10.4 months with placebo (P<.001). The 24-month overall survival (OS) rate was 91% with niraparib versus 85% with placebo. Based on these positive results, the investigators analyzed the overall population in the study, Gonzalez-Martin says.

In all patients, the median PFS was 13.8 months with niraparib versus 8.2 months with placebo (P<.001). There was a 38% reduction in the risk of progression or death in patients who received niraparib maintenance. The median OS rate in the overall population was 84% with niraparib versus 77% with placebo.

For more information on these data and other findings from PRIMA:https://www.targetedonc.com/conference/esmo-2019/pfs-improved-with-frontline-niraparib-maintenance-in-ovarian-cancer.